证券代码：300970 证券简称：华绿生物 公告编号：2025-011 二、董事会审议情况 经与会董事认真审议，形成如下决议： （一）审议通过了《关于<公司 2024 年度总经理工作报告>的议案》 经审核，董事会认为：2024 年度公司以总经理为代表的管理层有效地执行 了董事会的各项决议，该报告客观、真实地反映了管理层 2024 年度主要工作。 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 （二）审议通过了《关于<公司 2024 年度董事会工作报告>的议案》 公司独立董事张英明先生、刘芝玉先生及杨焱女士分别向董事会递交了 《2024 年度独立董事述职报告》，并将在公司 2024 年年度股东大会上述职。 江苏华绿生物科技集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十三次会议于 2025 年 4 月 23 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2025 年 4 月 15 日以通讯方式向全体 ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-014 江苏华绿生物科技集团股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 江苏华绿生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五届董事会第十三次会议及第五届监事会第十一次会议，分别审议 通过了《关于 2024 年度拟不进行利润分配的议案》，本议案尚需提交公司 2024 年年度股东大会审议。现将具体情况公告如下： 一、2024 年度利润分配预案基本情况 经致同会计师事务所（特殊普通合伙）审计，并出具标准无保留意见的《2024 年度审计报告》确认，公司 2024 年度合并报表归属于上市公司股东的净利润为 -47,565,525.06 元，2024 年度母公司的净利润为 263,908,344.09 元。截至 2024 年 12 月 31 日，合并报表归属于上市公司股东的累计未分配利润为 437,710,562.97 元，母公司累计未分配利润为 238,102,442.44 元。 依照《公司法》《上 ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2533.55万股，累计占流通股比： 27.33%，较上期变化： -228.76万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.4100 | 0.2600 | -257.69 | 0.6700 | | 每股净资产（元） | 12.41 | 13.13 | -5.48 | 12.94 | | 每股公积金(元) | 7.62 | 7.41 | 2.83 | 7.23 | | 每股未分配利润(元) | 3.64 | 4.54 | -19.82 | 4.52 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 10.32 | 9.96 | 3.61 | 7.52 | | 净利润(亿元) | -0.48 | 0.3 | -260 | 0.78 | | 净资产收益率(%) | -3.19 | 1. ...

Financial Performance - The company reported a net profit attributable to shareholders of -47,565,525.06 RMB for the year 2024, a decrease of 256.73% compared to 2023[3]. - The decline in net profit was primarily due to a significant drop in the sales price of the main product, enoki mushrooms, influenced by market conditions in the vegetable and edible mushroom sectors[3]. - The company's operating revenue for 2024 was ¥1,032,111,560.17, representing a 3.60% increase compared to ¥996,221,375.81 in 2023[19]. - The net profit attributable to shareholders for 2024 was -¥47,565,525.06, a decrease of 256.73% from ¥30,348,940.26 in 2023[19]. - The net cash flow from operating activities decreased by 17.32% to ¥137,798,307.93 in 2024 from ¥166,672,655.98 in 2023[19]. - The total assets at the end of 2024 increased by 8.80% to ¥2,305,515,184.73 compared to ¥2,118,970,407.99 at the end of 2023[19]. - The weighted average return on equity for 2024 was -3.19%, down from 1.98% in 2023, indicating a significant decline in profitability[19]. - The company reported a basic earnings per share of -¥0.41 for 2024, a decrease of 257.69% from ¥0.26 in 2023[19]. - The gross profit margin for edible mushrooms decreased by 7.56% to 5.96%[59]. Revenue and Sales - The company achieved a sales volume of 230,000 tons during the reporting period, representing a year-on-year increase of 21.28%[52]. - The total sales revenue reached 1,032,111,560.17 CNY, marking the first time it surpassed the 1 billion CNY threshold, with a year-on-year growth of 3.60%[56]. - The company’s main product, enoki mushrooms, generated revenue of 713,752,000.76 CNY, accounting for 69.15% of total sales, with a growth of 1.80% compared to the previous year[56]. - The company reported a significant increase in revenue from the "Others" category, which rose by 157.09% to ¥15,498,664.89[59]. Costs and Expenses - Cumulative expenses of approximately 20 million RMB were recognized due to the implementation of the 2022/2023 incentive plan, contributing to the overall decline in gross profit margin[3]. - The total cost of sales increased by 12.48% to ¥972,796,670.86, with direct raw materials accounting for 37.23% of total costs[63]. - The company experienced increased depreciation expenses due to the completion and capitalization of certain projects during the reporting period[3]. - The company’s financial expenses surged by 5,707.10% to ¥7,939,015.98, primarily due to increased lease liability interest expenses[67]. Strategic Plans and Market Position - The company plans to complete and put into operation its facilities in Henan and Guangxi in the second half of 2024, which is expected to drive revenue growth[42]. - The company is facing challenges due to increased competition and market fluctuations, necessitating strategic adjustments to maintain its market position[31]. - The company aims to enhance production levels at existing bases and deepen the national sales network, focusing on a multi-variety strategy for mushroom production[85]. - By 2025, the company plans to consolidate its leading position in the mushroom industry and expand its product line, particularly in factory-cultivated mushrooms and processed products[86]. Research and Development - The company invested over 14.6 million CNY in R&D, resulting in the addition of 21 new patents, enhancing its technological strength and intellectual property protection[53]. - The R&D team is composed of experienced professionals from agriculture, food, and biology, supporting the company's innovation efforts[41]. - The company has signed contracts for hybrid breeding of new strains of yellow enoki mushrooms, aiming to develop 1-2 patented strains suitable for industrial cultivation[68]. - The company will continue to invest in R&D to improve technology levels and increase biological conversion rates and yield per bottle in mushroom cultivation[87]. Governance and Compliance - The company has established a comprehensive internal control system to ensure product traceability and minimize food safety risks[91]. - The board of directors consists of 9 members, including 3 independent directors, and operates in accordance with relevant laws and regulations[98]. - The company has established an independent financial management department, ensuring autonomous financial decision-making and compliance with accounting standards[103]. - The company has implemented a robust investor relations management system, enhancing communication and transparency with investors[100]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating compliance with environmental regulations[150]. - The company has adhered to multiple environmental protection laws and standards, ensuring all construction projects meet environmental impact assessment requirements[152]. - The company has implemented a wastewater treatment system that adheres to the principle of "separation of clean and dirty water," ensuring that treated wastewater meets discharge standards before being used for landscaping[155]. - The company has established an environmental self-monitoring plan, with automatic monitoring devices installed to ensure compliance with relevant emission standards[156]. Social Responsibility - The company aims to provide more job opportunities for disadvantaged groups, continuing to support poverty alleviation and rural revitalization efforts[164]. - The establishment of a "mushroom bottling workshop" in Chongqing has created a demonstration workshop for employment assistance, successfully absorbing local impoverished labor[163]. - The company emphasizes the importance of connecting poverty alleviation results with rural revitalization, enhancing local economic self-sufficiency[163]. - The company has committed to fulfilling its social responsibilities by stabilizing and expanding employment positions, linking upstream and downstream industries[163]. Shareholder Relations - The company has a clear strategy for managing share transfers and reductions to ensure compliance with legal requirements[173]. - The company will ensure compliance with all relevant laws and regulations regarding share transactions and investor protection[177]. - The company will compensate investors for direct losses incurred due to reliance on commitments that were not fulfilled[181]. - The company actively protects shareholder rights by adhering to legal requirements for timely and accurate information disclosure, enhancing transparency through various communication channels[158].

Financial Performance - The company's revenue for Q1 2025 was ¥270,596,190.27, representing a 5.33% increase compared to ¥256,905,255.97 in the same period last year[4] - Net profit attributable to shareholders decreased by 11.20% to ¥1,544,654.24 from ¥1,739,546.28 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 38.07% to ¥1,128,975.92 from ¥817,696.94 in the previous year[4] - Total operating revenue for the current period reached ¥270,596,190.27, an increase of 5.3% compared to ¥256,905,255.97 in the previous period[18] - Net profit for the current period was ¥1,964,285.37, a decrease of 19.1% from ¥2,427,205.96 in the previous period[19] Cash Flow and Assets - The net cash flow from operating activities rose by 9.67% to ¥39,057,383.54 compared to ¥35,613,948.24 in the same period last year[4] - The net cash flow from operating activities was ¥39,057,383.54, compared to ¥35,613,948.24 in the previous period, indicating an increase of 6.8%[20] - The company reported a net cash flow from investing activities of -¥36,008,467.83, an improvement from -¥50,383,705.09 in the previous period[22] - Cash and cash equivalents at the end of the period totaled ¥370,068,084.65, up from ¥336,898,188.19 at the end of the previous period[22] - The company's total assets reached ¥2,307,326,846.86, compared to ¥2,305,515,184.73 in the previous period, showing a slight increase[16] Shareholder Information - The company reported a total of 10,189 common shareholders at the end of the reporting period[8] - The largest shareholder, Yu Yangchao, holds 30.27% of the shares, totaling 36,387,628 shares[9] - The company plans to repurchase shares using between RMB 30 million and RMB 60 million, with a total of 2,346,600 shares repurchased, accounting for 1.99% of the total share capital[12] - The company has completed the share repurchase plan as of the reporting period[12] - The company aims to enhance investor confidence and align interests through the share repurchase program[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥2,307,326,846.86, a slight increase of 0.08% from ¥2,305,515,184.73 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 0.29% to ¥1,496,358,459.85 from ¥1,492,022,748.07 at the end of the previous year[4] - The company's total liabilities were RMB 783,179,491.98, slightly down from RMB 786,123,172.76 at the beginning of the period[15] - The equity attributable to shareholders of the parent company was ¥1,496,358,459.85, up from ¥1,492,022,748.07, reflecting a growth of 0.2%[16] Earnings Per Share - The basic earnings per share decreased by 50.00% to ¥0.01 from ¥0.02 in the same period last year[4] - Basic and diluted earnings per share for the current period were both ¥0.01, down from ¥0.02 in the previous period[20] Operating Costs - Total operating costs amounted to ¥271,307,730.48, up from ¥257,780,429.22, reflecting a rise of 5.2%[18] Asset Composition - The company's current assets totaled RMB 602,163,314.71, up from RMB 579,976,110.79 at the beginning of the period[13] - The company's non-current assets decreased from RMB 1,725,539,073.94 to RMB 1,705,163,532.15 during the same period[13] - The company's cash and cash equivalents increased to RMB 373,324,620.90 from RMB 361,137,972.25[13] - Accounts receivable rose to RMB 20,004,757.55 from RMB 16,696,728.60, indicating a growth in receivables[13]

江苏华绿生物科技集团股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） 目 录 | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-84 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 一、审计意见 我们审计了江苏华绿生物科技集团股份有限公司（以下简称华绿生物公 司）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度 的合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表 以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了华绿生物公司 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年度的合并及公司经 ...

致同会计师事务所（特殊普通合伙） 目 录 专项核查报告 公司 2024 年度营业收入扣除情况表及说明 1-3 江苏华绿生物科技集团股份有限公司 营业收入扣除情况表 专项核查报告 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 江苏华绿生物科技集团股份有限公司 营业收入扣除情况表专项核查报告 致同专字（2025）第 371A009355 号 江苏华绿生物科技集团股份有限公司全体股东： 我们接受委托，在审计了江苏华绿生物科技集团股份有限公司（以下简 称"华绿生物公司"）2024 年 12 月 31 日的合并及公司资产负债表，2024 年度 的合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表 以及财务报表附注的基础上，对后附的《华绿生物公司 2024 年度营业收入扣 除情况表及说明》（以下简称"营业收入扣除情况表"）进行了专项核查。 按照《深圳证券交易所股票上市规则》、《深圳证券交易所创业板股票 上市规则》（以下简称 ...

江苏华绿生物科技集团股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字（2025）第 371A015368 号 江苏华绿生物科技集团股份有限公司全体股东： 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性 发表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，华绿生物公司于 2024 年 12 月 31 日按照《企业内部控制基本 规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 此页无正文，本专项说明仅供华绿生物公司披露年度 ...

中信证券股份有限公司 关于江苏华绿生物科技集团股份有限公司 2024年度内部控制评价报告的核查意见 中信证券股份有限公司（以下简称"中信证券""保荐机构"）作为江苏 华绿生物科技集团股份有限公司（以下简称"华绿生物""公司"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等相关规定，对《江苏华绿生物科技 集团股份有限公司2024年度内部控制评价报告》（以下简称"内部控制评价报 告"）进行了核查，现就内部控制评价报告出具核查意见如下： 一、保荐机构核查工作 中信证券保荐代表人采取查阅公司与财务报告和信息披露事务相关的内部 控制制度、抽查内部控制过程记录文件等方式，结合日常的持续督导工作，在 对公司内部控制的完整性、合理性及有效性进行合理评价基础上，对公司董事 会出具的内部控制评价报告进行了核查。 二、公司内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高 风险领域。 纳入评价范围的主要单位为公司合并报表范围内的全部单位，包括：江苏 华绿生 ...

关于江苏华绿生物科技集团股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所（特殊普通合伙） 目 录 关于江苏华绿生物科技集团股份有限公司非经营性资金占用及其 他关联资金往来的专项说明 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 关于江苏华绿生物科技集团股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字（2025）第 371A009353 号 江苏华绿生物科技集团股份有限公司全体股东： 江苏华绿生物科技集团股份有限公司 2024 年度非经营性资金占用 及其他关联资金往来情况汇总表 1 我们接受江苏华绿生物科技集团股份有限公司（以下简称"华绿生物公 司"）委托，根据中国注册会计师执业准则审计了华绿生物公司 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度合并及公司利润表、合并及公司现 金流量表、合并及公司股东权益变动表和财务报表附注，并出具了致同审字 （202 ...